Rare Central Nervous System Cancers Initiative

美国国立卫生研究院特别适合创建一个罕见的中枢神经系统癌症倡议。这项工作利用了NIH的以下具体资源。这就需要开发一个临床试验基础设施，包括数据管理系统，以监督特定疾病的治疗和自然史研究。计划与成像技术专家合作，创建成像生物标志物和常规成像，以监测治疗反应。组织库已经建立，用于存储肿瘤和正常组织的分子分析，包括基因组学，代谢组学和蛋白质组学，旨在促进对肿瘤生物学和发病机制的理解，从而获得更好的预后信息，亚分类和最终预测对特定治疗反应的标记。此外，已经开发了特定的测试功能，例如上面描述的CNS分子面板，并且正在开发其他测试。例如，预计将进行免疫治疗试验，免疫监测能力将需要作为该研究的关键组成部分。以nih为基础的外展工作将用于与患者倡导团体互动，以提高患者对这些工作的参与，并为教育项目提供场所，以提高患者和护理人员对其罕见疾病的了解。四项临床试验最近开放（17C0102免疫检查点抑制剂Nivolumab用于选择罕见中枢神经系统癌症患者；舒尼替尼用于肉瘤和胶质瘤；Marizomib用于rela融合室管膜瘤；Nivolumab用于高突变低级别胶质瘤，包括少突胶质细胞瘤）。

The NIH is uniquely suited to create a rare CNS cancer initiative. This effort utilizes the following specific resources of the NIH. This has required developing a clinical trial infrastructure, including data management system, to oversee the disease specific therapeutic and natural history studies. Collaborations with experts in imaging technologies to create imaging biomarkers and routine imaging for monitoring response to therapies are planned. A tissue repository has been established to store both tumor and normal tissue for molecular analyses including genomics, metabolomics, and proteomics with the intent of advancing the understanding of tumor biology and pathogenesis leading to better prognostic information, sub-classification and ultimately markers predictive of response to specific treatments. Additionally, specific testing capabilities have been developed such as the CNS Molecular Panel described above and additional tests are under development. For example, an immunotherapy trial is anticipated and immunologic monitoring capabilities will be needed as a critical component of this study. NIH-based outreach efforts will be utilized to interact with patient advocacy groups to enhance patient participation in these efforts and provide a venue for educational programs to improve patient and caregiver understanding of their uncommon disease. Four clinical trials are recently open (17C0102 Immune Checkpoint Inhibitor Nivolumab in People With Select Rare CNS Cancers; Sunitinib for Sarcoma and Gliosarcoma; Marizomib for RELA-fused ependymoma; and Nivolumab for Hypermutated Lower Grade Glioma including oligodendroglioma.